JP2020530306A5 - - Google Patents
Info
- Publication number
- JP2020530306A5 JP2020530306A5 JP2020520430A JP2020520430A JP2020530306A5 JP 2020530306 A5 JP2020530306 A5 JP 2020530306A5 JP 2020520430 A JP2020520430 A JP 2020520430A JP 2020520430 A JP2020520430 A JP 2020520430A JP 2020530306 A5 JP2020530306 A5 JP 2020530306A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- scfv domain
- quadruspecific
- binding specificity
- percentage homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024064619A JP7685095B2 (ja) | 2017-06-25 | 2024-04-12 | 多重特異性抗体とその作製及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524558P | 2017-06-25 | 2017-06-25 | |
| US62/524,558 | 2017-06-25 | ||
| PCT/US2018/039157 WO2019005640A2 (en) | 2017-06-25 | 2018-06-22 | MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024064619A Division JP7685095B2 (ja) | 2017-06-25 | 2024-04-12 | 多重特異性抗体とその作製及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530306A JP2020530306A (ja) | 2020-10-22 |
| JP2020530306A5 true JP2020530306A5 (enExample) | 2022-02-07 |
| JP7474193B2 JP7474193B2 (ja) | 2024-04-24 |
Family
ID=64742656
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520430A Active JP7474193B2 (ja) | 2017-06-25 | 2018-06-22 | 多重特異性抗体とその作製及び使用方法 |
| JP2024064619A Active JP7685095B2 (ja) | 2017-06-25 | 2024-04-12 | 多重特異性抗体とその作製及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024064619A Active JP7685095B2 (ja) | 2017-06-25 | 2024-04-12 | 多重特異性抗体とその作製及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200157224A1 (enExample) |
| EP (1) | EP3645048A4 (enExample) |
| JP (2) | JP7474193B2 (enExample) |
| KR (1) | KR102838340B1 (enExample) |
| CN (3) | CN117946277A (enExample) |
| AU (1) | AU2018295119B2 (enExample) |
| CA (1) | CA3068049A1 (enExample) |
| IL (1) | IL271260B2 (enExample) |
| SG (1) | SG11201912865VA (enExample) |
| WO (1) | WO2019005640A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260008861A9 (en) * | 2017-06-25 | 2026-01-08 | Systimmune, Inc. | Anti-4-1bb antibodies and methods of making and using thereof |
| US11787863B2 (en) * | 2017-06-25 | 2023-10-17 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| US11535667B2 (en) * | 2017-08-28 | 2022-12-27 | Systimmune, Inc. | Anti-CD3 antibodies and methods of making and using thereof |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
| AU2020379735A1 (en) | 2019-11-05 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | N-terminal SCFV multispecific binding molecules |
| CN118580364A (zh) * | 2019-11-06 | 2024-09-03 | 西雅图免疫公司 | 制导和导航控制蛋白及其制备和使用方法 |
| US11976133B2 (en) * | 2020-01-31 | 2024-05-07 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| TWI908779B (zh) * | 2020-03-17 | 2025-12-21 | 美商西雅圖免疫公司 | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 |
| BR112023005152A2 (pt) | 2020-09-21 | 2023-04-25 | Systimmune Inc | Anticorpo biespecífico com especificidade intensificada (seba) |
| EP3988568A1 (en) * | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
| EP4352108A4 (en) * | 2021-06-09 | 2026-01-07 | Shanghai Epimab Biotherapeutics Co Ltd | BISPECIFIC ANTIBODIES AND BINDING PROTEINS THAT BIND TO OX40 AND/OR PD-L1 MOLECULES |
| TWI833244B (zh) * | 2021-06-18 | 2024-02-21 | 大陸商和鉑醫藥（上海）有限責任公司 | 一種雙抗組合及其應用 |
| CN118974091A (zh) * | 2022-04-11 | 2024-11-15 | 阿斯利康(瑞典)有限公司 | T细胞结合蛋白 |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
| CN118667026A (zh) * | 2023-03-15 | 2024-09-20 | 三生国健药业（上海）股份有限公司 | 抗muc17*cd3*cd28三特异性抗体 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| WO2007002223A2 (en) * | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| WO2008119567A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| WO2008119565A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| US8178101B2 (en) * | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| KR20180005753A (ko) * | 2008-06-25 | 2018-01-16 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체 |
| SG176219A1 (en) | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
| CN103906533A (zh) * | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | 多特异性和多价结合蛋白及其用途 |
| HK1218549A1 (zh) * | 2013-06-26 | 2017-02-24 | Numab Therapeutics AG | 新型抗体框架 |
| JP6693872B2 (ja) * | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス，インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| JP6510532B2 (ja) * | 2013-12-20 | 2019-05-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性ｈｅｒ２抗体及び使用方法 |
| CA3265373A1 (en) * | 2014-02-20 | 2025-10-30 | H. Lundbeck A/S | Anti-acth antibodies and use thereof |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| US9885721B2 (en) * | 2014-05-29 | 2018-02-06 | Spring Bioscience Corporation | PD-L1 antibodies and uses thereof |
| EP3174897B1 (en) * | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| EP3253790A4 (en) | 2015-02-06 | 2018-07-25 | University of Maryland, Baltimore | Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| WO2017011342A1 (en) * | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| JP6932700B2 (ja) | 2015-09-15 | 2021-09-08 | アムジエン・インコーポレーテツド | ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用 |
| ES2819870T3 (es) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Moléculas de unión con cadena J modificada |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| CN106397598B (zh) * | 2016-02-23 | 2020-07-14 | 上海交通大学 | 多价多特异性抗体及免疫杂合蛋白的表达和制备方法 |
| US11787863B2 (en) * | 2017-06-25 | 2023-10-17 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
-
2018
- 2018-06-22 SG SG11201912865VA patent/SG11201912865VA/en unknown
- 2018-06-22 CN CN202410190782.3A patent/CN117946277A/zh active Pending
- 2018-06-22 CN CN201880039406.7A patent/CN110799540B/zh active Active
- 2018-06-22 AU AU2018295119A patent/AU2018295119B2/en active Active
- 2018-06-22 CN CN202410191002.7A patent/CN117946278A/zh active Pending
- 2018-06-22 EP EP18822881.1A patent/EP3645048A4/en active Pending
- 2018-06-22 CA CA3068049A patent/CA3068049A1/en active Pending
- 2018-06-22 IL IL271260A patent/IL271260B2/en unknown
- 2018-06-22 JP JP2020520430A patent/JP7474193B2/ja active Active
- 2018-06-22 KR KR1020207002348A patent/KR102838340B1/ko active Active
- 2018-06-22 WO PCT/US2018/039157 patent/WO2019005640A2/en not_active Ceased
- 2018-06-22 US US16/615,123 patent/US20200157224A1/en active Pending
-
2024
- 2024-04-12 JP JP2024064619A patent/JP7685095B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530777A5 (enExample) | ||
| JP2020529864A5 (enExample) | ||
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| CN117285641A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| WO2023056312A1 (en) | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof | |
| JP2021501575A (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| CN117222672A (zh) | 抗cldn4-抗cd137双特异性抗体 | |
| HK40111323A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40111322A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40093821A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40088418A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40088417A (en) | Multi-specific antibodies and methods of making and using thereof | |
| WO2025064498A1 (en) | Affinity-modulated anti-cd45 x pd-1 and anti-cd43 x pd-1 bispecific antibodies to treat cancer and autoimmunity | |
| NZ760913B2 (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40097105A (en) | Bispecific antibodies and methods of making and using thereof | |
| HK40073540A (zh) | 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法 | |
| HK40018991A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40019010A (en) | Multi-specific antibodies and methods of making and using thereof |